A Korean biotech firm Orandbio, specializing in advanced biomaterials for regenerative medicine and combination medical products, secured investment from Genaxis.

Orandbio possesses cutting-edge technologies including bioactive particle processing, anti-inflammatory biodegradable polymers, and bio-functional scaffolds for tissue regeneration. The company is actively developing medical devices and tissue-engineered products targeting kidneys, knees, bones, teeth, and various regenerative tissues/organs.

Its flagship product, CharmRenal, uniquely restores kidney function from around 15% back to between 30% and 50%, preventing or treating dialysis and chronic kidney disease, aiming to become a global first-in-class treatment. Another significant product, CharmCarti, targets osteoarthritis stages 2 (moderate) and 3 (severe), reducing joint friction and inflammation, alleviating pain, and promoting cartilage regeneration, aiming to achieve best-in-class status.

Additionally, Orandbio develops diverse medical products like the high-performance bone graft CharmOss and periodontal tissue regenerative scaffold CharmGuide, alongside tissue-engineered solutions such as regenerative kidney (CharmKidney), joint cartilage (CharmChon), nerves (CharmNerve), and bone (CharmBone).

In April 2025, Orandbio developed a novel anti-inflammatory and antioxidant scaffold incorporating PDRN and melatonin. This scaffold creates an ovarian-like environment, promoting blood vessel formation, suppressing reactive oxygen species, and effectively restoring ovarian function. Animal studies demonstrated significant normalization of ovarian function and hormone levels post-chemotherapy, culminating in successful pregnancy outcomes. This groundbreaking research was published in Advanced Healthcare Materials (AHM) on April 14, 2025.

By 2026, Orandbio plans preclinical trials for CharmRenal and CharmCarti, establishing GMP OEM production systems for periodontal regeneration products, securing key sales channels, and expanding governmental project funding. In 2027, the company expects regulatory approval and market release of synthetic and xenograft bone grafts (CharmOss-S, CharmOss-B) and the periodontal regeneration scaffold (CharmGuide), further solidifying market leadership through clinical trials for innovative periodontal regeneration products.

Genaxis commented, “Orandbio holds substantial patents and SCIE-level publications in biomaterials and regenerative medicine, supported by a robust clinical advisory network from top university hospitals, indicating high growth potential in medical devices and tissue engineering.”